Experience

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $350 million 7.350% senior notes due 2025. Zhenro Properties Group…

Davis Polk advised the joint lead managers in connection with a $500 million Regulation S bonds offering by Shui On Development (Holding) Limited of its 6.150% senior notes due 2024…

Davis Polk advised the initial purchasers in connection with a $200 million Regulation S high-yield offering by KWG Group Holdings Limited of its 5.950% senior notes due 2025. KWG Group…

Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in Innovent Biologics, Inc., for an aggregate consideration of…

Davis Polk advised the initial purchasers in connection with a $300 million Regulation S offering by CIFI Holdings (Group) Co. Ltd. of its 5.950% senior notes due 2025. Established in 2000…

Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $200 million 8.300% senior notes due 2023. Zhenro Properties Group…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $200 million 8.350% senior notes due 2024. Concurrently with the…

Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…